Sentences with phrase «of effect of drug»

The results don't indicate whether one causes the other, but they do show that connectivity patterns could one day help predict traits or offer broad indicators of the effect of drugs on the brain.

In an effort to increase community members» awareness of the effects of drug and alcohol abuse, the reservation hosted a three - day workshop on substance abuse.

Cardiovascular pharmacology: This branch of pharmacology deals with the study of the effects of drugs on the human's cardiovascular system, including the heart and blood vessels.

Because of the effects of drugs and alcohol on the brain, simply stopping is not as easy as it sounds.

Not exact matches

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

Earlier this year Merck halted trials on its once - promising Alzheimer's drug after an independent panel of ruled there was «virtually no chance of finding a positive clinical effect.»

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

To balance out the effects of men's low testosterone levels while taking the drug, the patients were given a synthetic androgen, or male steroid hormone, to help them maintain their «male» characteristics.

Merck is the latest company to weather bad news in the Alzheimer's drug race, halting a late - stage trial yesterday in an experimental amyloid - targeting candidate called verubecestat after a data monitoring committee said there was «virtually no chance of finding a positive clinical effect,» Reuters reported.

Companies like U.S. biotech giant Gilead and the U.K.'s GlaxoSmithKline (the majority stakeholder in global HIV partnership ViiV Healthcare) have developed drugs that drastically lower the chance of HIV infection — or which simply lower the number of drugs you have to take to treat it, consequently curbing the risk of toxic side effects while simplifying medical regimens.

They found that antibodies in the vaccine bound to the heroin before crossing the blood - brain barrier, thus preventing the euphoric effects of the drug.

UniQure, for example, has developed a drug called Glybera, which is essentially a virus that reverses the effects of LPLD, a disease that prevents people from breaking down fats and can cause increased risk of pancreatitis.

The drug is particularly valuable to insurance companies, who will pay top dollar for treatments that help patients avoid the ravaging and expensive - to - treat effects of Hepatitis C.

The pink pill, which boosts dopamine and norepinephrine (both catalysts for sexual excitement) while reducing the inhibitory effects of serotonin in the brain's prefrontal cortex, is the first — and so far only — female libido drug to win FDA approval.

The new offering, «Watson for Patient Safety,» will gobble up anonymized medical records, claims data, and millions of electronic submissions to the FDA about potential drug side effects (known as individual case safety reports) to see if it can learn about the hidden dangers of medicines before they become too costly.

He also noted that many drugs aimed at lessening the effects of Alzheimer's disease work by attempting to improve this attention mechanism.

For decades, naloxone, a drug approved in 1971 that instantly reverses the effect of opioid overdose, languished in relative obscurity.

For future studies, they suggested, researchers should test the performance of doped chess players given a much longer time limit, so the study could isolate the positive effects of brain drugs.

Studies have found that longer sentences do not have appreciably greater deterrent effects; many serious crimes are committed by people under the influence of alcohol or drugs, who are not necessarily thinking of the consequences of their actions, and certainly are not affected by the difference between a 15 - year and a 30 - year sentence.

The opioid antagonist Naloxone, or Narcan, instantly stops the effects of a drug overdose when administered.

The density of the patient's skin and muscle slows the drug's progress, allowing it to be dispersed throughout the body in a wide spiderweb pattern, thereby hastening its effect.

«Hitler was not insane or deranged, or suffering from drug - induced delusions,» he writes, «or laboring under the effects of some chronic disease such as syphilis, or acting in an unresolved hypnotic trance: on the contrary, he was sane according to any reasonable definition of the term, and fully responsible for his actions.»

In addition to partnering with Celgene (celg) to better track negative drug side effects, IBM (ibm) is applying its cognitive computing AI technology to recommend cancer treatment in rural areas in the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson Health.

The treaty, which is still in effect, requires all countries part of the treaty to «prevent and combat» drugs and drug addicts and to enforce punishment against the unauthorized cultivation, production or possession of opium, coca (and its derivative cocaine), marijuana and other illegal substances.

Agios Pharmaceuticals shares plunged more than 18 percent after the company discontinued development of an experimental drug for rare blood disorder due to side effects seen in a study.

Shaked said Israeli authorities would now put their focus on education about the possible harmful effects of drug use.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The side effect was first observed earlier this month at the American Society of Hematology conference, where CEODavid Schenkein spoke with CNBC about the safety of one of the molecules in its drug, which was meant to treat pyruvate kinase deficiency, a rare, genetic anemia.

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol.

A more leftist system of greater drug price regulation could come with other negative side - effects, Miller continued.

In an editorial accompanying the new study, Dr. Wilson Compton of the National Institute on Drug Abuse in Bethesda, Maryland, and colleagues say policymakers need to understand which parts of medical marijuana laws are tied with positive and negative effects.

She said that employers» increased use of high - deductible plans, one of the side - effects of the law, has resulted in patients paying more out of pocket for the drug, and that's «where you're seeing a lot of noise around EpiPen.»

KeyBioscience designed these drugs, which include BP - 089 and KBP - 056, to have the same broad mechanism of action as KBP - 042 but deliver different effects or potency because of changes to their engineering.

Our Government is also committed to ensuring that drug labels are written in plain language, and that the potential side effects of medication are accurately indicated.

«There's no other injectable drug that works like that,» Lewin said of Isuprel, and other drugs may have unwanted side effects, he said.

Small drugmaker Portola Pharmaceuticals this month applied for U.S. approval of a drug called andexanet alfa that rapidly reverses the effect of Xarelto and Eliquis.

These healthcare brands will have the effect of soothing out the inevitable fluctuations that occur on the pharmaceutical side, though right now, Glaxo's portfolio is boasting robust growth from small - scale HIV drugs Triumeq and Trivicay (which, as the CEO noted in the last annual report, sport year - over-year sales growth of 41 % and 43 %, respectively).

The effect of substitutes is dependent on the individual drug.

Doctors often use a combination of off - label drugs to try to manage patients» nightmares, flashbacks and depression, but the drugs do nothing to treat the underlying condition, and can have negative side effects.

The charges suggest that a small group of health - care firms — ones that acquire the rights to drugs and significantly increase their prices — is drawing the scrutiny of regulators and prosecutors, with a possible chilling effect on aggressive drug - pricing strategies.

According to Living Goods, clients may also be reluctant to buy drugs from other private providers because of the risk of getting a counterfeit medicine.63 Living Goods sent us a study conducted at the midline of its RCT that claims that both availability of counterfeit drugs and drug prices decreased at private retailers in areas where CHPs worked.64 According to the study, about 37 % of private drug shops in the areas it studied sold fake ACT drugs, 65 and availabilty of fake ACTs was about 50 % lower among non-Living Goods sellers in the areas where Living Goods worked.66 Additional results on these potential effects will be made available when the full RCT is published.

Martin Shkreli, the founder and chief executive of Turing, said that the drug is so rarely used that the impact on the health system would be minuscule and that Turing would use the money it earns to develop better treatments for toxoplasmosis, with fewer side effects.

Every year the FDA monitors the testing of 3,000 new drugs on nearly 200 million people to determine their effects.

The existing drugs for osteoarthritis cause a high frequency of stomach ulcers and other side effects such as high blood pressure.

If there is a competitive drug market, with limited advantage offered by the new drug in terms of increased effectiveness or reduced side effects, the drug will probably not win substantial market share in its product category.

Nevertheless, prescription drugs CPI is only 1.37 % of the aggregate index (according to a BLS official at the time of writing), thus the overall effect on medical care inflation and headline aggregate index should be limited.

As the Astra Zeneca Pfizer deal gets more bad tempered and political, what are the side effects of this massive drug firm deal?

ALKS 3831 is a treatment for schizophrenia that avoids the side effects of weight gain and metabolic problems that the incumbent drug has, and a phase 3 trial for it should read out in the fall of 2018.

Perhaps so many of these new drugs fail to have an effect because the basic research on which their development was based isn't valid.

Drug company scientists develop a drug with a range of physiological effects, none of which are terribly helpful, so the marketers must identify and promote a disease for the drug to treatDrug company scientists develop a drug with a range of physiological effects, none of which are terribly helpful, so the marketers must identify and promote a disease for the drug to treatdrug with a range of physiological effects, none of which are terribly helpful, so the marketers must identify and promote a disease for the drug to treatdrug to treat....